NovoCure (NVCR) announced results from its Phase 3 EF-14 trial adding Optune to standard temozolomide chemotherapy for the treatment of newly diagnosed glioblastoma on Sunday. The results show a consistent and maintained improvement in overall survival at two, three, four and five years.
from RTT - Before the Bell http://ift.tt/2o5ns2r
via IFTTT
No comments:
Post a Comment